Introduction
Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the axial skeleton. The most common clinical manifestation is inflammatory low back pain secondary to involvement of the sacroiliac joint. Ankylosing spondylitis primarily affects men, and its incidence peaks in the third and fourth decades of life. 1 Reported estimates of worldwide prevalence range as high as 0.9%. 2 The diagnosis is established on the basis of the New York Criteria for diagnosing ankylosing spondylitis: chronic inflammatory low back pain, clinical limitation of motion of the lumbar spine and chest expansion, and radiologic sacroiliitis. 3 Involvement of peripheral joints as well as enthesopathies also might occur.
Evaluation of extra-articular manifestations of ankylosing spondylitis is also important when considering different treatment options. The most common of these are anterior uveitis, psoriatic arthritis, inflammatory bowel disease, and pulmonary and renal abnormalities. 4 Recent studies have found that sensorineural hearing loss (SNHL) also might be a manifestation of ankylosing spondylitis, although this association is controversial. 5, 6 The physiopathologic mechanism of this hearing impairment is not yet clear; nevertheless, it has been suggested that it might be the result of vasculitis, granulomatous inflammation, or autoantibody production. It has been demonstrated that immune complexes are present in the sera of ankylosing spondylitis patients with SNHL, leading to the supposition that deposition of these circulating immune complexes in the inner ear or labyrinthine vessels could result in vasculitis or ischemic damage.
Studies also have found that when patients with ankylosing spondylitis had their hearing evaluated by measurement of otoacoustic emissions, findings were significantly different from those of controls. 1, 8 These patients exhibited hearing loss, particularly in the higher frequencies, and this might have indicated the presence of an injury to the outer hair cells. Similar findings were suggested when ankylosing spondylitis patients were assessed by audiometry, although a detailed hearing profile for these patients has not yet been obtained. 5 In this article, we describe our study of the auditory function of patients with ankylosing spondylitis and our comparison of it with that of healthy controls based on the results of audiometry and tympanometry. Another objective was to explore any correlations between hearing thresholds and disease activity and functional indices in patients with ankylosing spondylitis.
Patients and methods
For this observational case-control study, we identified patients who had been diagnosed with ankylosing spondylitis at a rheumatology outpatient clinic in a tertiary care teaching hospital in 2013 and 2014. We randomly selected for study 30 such patients-18 men and 12 women, aged 25 to 58 years (mean: 46.5). We then recruited a socially and demographically matched control group of 30 healthy persons-11 men and 19 women, aged 18 to 57 years (mean: 40.0)-for comparison purposes; the controls had been accompanying the ankylosing spondylitis patients to their consultations at the clinic.
We excluded patients younger than 18 years and older than 60 years, as well as those presenting with a hearing impairment for which the cause was suspected-for example, noise-induced hearing loss, sudden hearing loss, otosclerosis, or a congenital hearing deficit.
History. We compiled information on the onset of symptoms, the time of diagnosis, and the types of medications used to treat ankylosing spondylitis.
Testing. All 60 participants underwent an otolaryngologic evaluation and were then administered a standard audiologic assessment, which consisted of pure-tone audiometry at eight frequencies (0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz), speech audiometry, and tympanometry. Speech audiometry included measurements of the speech reception threshold and the word recognition score, including during tests in noise.
Questionnaires. As part of the assessment of the ankylosing spondylitis patients, we obtained scores on the Bath ankylosing spondylitis disease activity index (BASDAI) 9 and the Bath ankylosing spondylitis functional index (BASFI). 10 • The BASDAI questionnaire is made up of six questions-one each on fatigue, spinal pain, peripheral joint symptoms, entheseal pain, overall discomfort, and morning stiffness. Each question is scored on a visual analogue scale. The overall BASDAI score is calculated by adding the responses to the first four questions and the average of the final two questions and dividing the total by 5; possible scores range from 0 to 10. The BASDAI is considered one of the most important instruments for evaluating ankylosing spondylitis patients in clinical trials.
• The BASFI questionnaire consists of ten questions-eight on daily activities relating to functional anatomy and two on a patient's ability to cope with life. The overall score is the mean of all ten scores; again, possible scores range from 0 to 10.
BASDAI and BASFI scores of 4 or higher are considered to be predictive of greater disease activity and poorer functional status, respectively.
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Statistical analysis. Descriptive statistics were used to calculate the prevalence of the different tympanography patterns and the distribution of the different types of hearing loss for the right and left ear of each patient separately and for both groups collectively. Inferential statistics were also used for data analysis.
The chi-square test was used for evaluating sex, tympanography patterns, and the type of hearing loss (categorical variables). The Student t test was performed to assess all other variables (continuous variables). The Fisher exact test and the t test were used to evaluate BASDAI and BASFI scores among the ankylosing spondylitis patients. The Mann-Whitney U test was performed to compare the mean time from diagnosis to the initiation of treatment for each subgroup of patients treated with different classes of drugs. The level of significance was set at p < 0.05.
Ethical considerations. The study was approved by our center's Institutional Research Ethics Committee (protocol number: CAAE 33675714.0.0000.0096). All patients and controls were informed of the nature of the research protocol, and all signed a form attesting to free and informed consent.
Results
Among the 60 ears in the ankylosing spondylitis patients, 10 (16.7%) demonstrated a mean air-conduction threshold of 25 dB or higher at 0.5, 1, 2, and 4 kHz, compared with only 1 ear (1.7%) in the control group. Overall, the average of the mean air-conduction thresholds 0.5, 1, 2, and 4 kHz was 16.73 dB in the case group and 12.35 in the control group; the difference was statistically significant (p = 0.004) (table 1). When thresholds were compared separately for each frequency, the case group had significantly higher thresholds at the higher frequencies: 3 kHz (p = 0.018), 4 kHz (p < 0.001), 6 kHz (p < 0.001), and 8 kHz (p = 0.001) (figure).
Within the case group, 13 ears (21.7%) were diagnosed with a hearing impairment; 10 of these hearing losses were classified as pure SNHL and 3 as mixed hearing loss. In the control group, only 1 ear (1.7%) was detected with hearing impairment, which was classified as SNHL.
We also divided the case and control groups into two subgroups each. One subgroup was made up of persons with normal hearing thresholds and the other was made up of persons with a hearing impairment of any type and degree. We found a statistically significant trend toward a higher prevalence of hearing loss among the case patients (p = 0.002).
A standard type A tympanogram was found in 56 ears in the case group (93.3%); of the rest, 2 were type Ad, 1 was type As, and 1 was type C. Among the control ears, 54 were standard type A (90.0%), 3 were type Ad (5%), and were 3 type As. There was no statistically significant difference between the two groups in the number of normal and abnormal tympanograms (p = 0.74).
Of the 30 ankylosing spondylitis patients, 12 (40.0%) were taking etanercept, 8 (26.7%) adalimumab, 6 sulfasalazine (20.0%), 5 infliximab (16.7%), 11 methotrexate (36.7%), 1 azathioprine (3.3%), and 5 another drug (e.g., a nonsteroidal anti-inflammatory drug, glucocorticoid, or analgesic); some were taking more than one agent. We grouped these patients into three categories: those who were taking a tumor necrosis factor-alpha inhibitor (anti-TNFα) only (i.e., etanercept, adalimumab, or infliximab), those who were using a combination of anti-TNFα and methotrexate, and those who were taking neither of these drugs. We found that patients who were taking only anti-TNFα had a significantly lower mean air-conduction threshold than those who were taking another drug (14.59 vs. 24.80; p = 0.01). All other comparisons revealed no statistically significant differences (table 2) . In addition, we found no statistically significant difference in the duration of disease among these subgroups (data not shown).
The overall mean BASDAI and BASFI scores in the ankylosing spondylitis patients were 4.53 and 5.87, respectively. In this group, 8 patients had hearing loss and 22 did not. The mean BASDAI scores were 4.98 for the case patients with hearing loss and 4.58 for those without-not a significant difference. The corresponding BASFI scores were 6.13 and 5.79-again not significant (table 3) .
Of the 8 case patients with hearing loss, 5 (62.5%) had a high BASDAI score (≥4) and 6 (75.0%) had a high BASFI score (≥4). Of the 22 without hearing loss, 14 (63.6%) had a high BASDAI score and 15 (68.2%) had a high BASFI score. None of the differences was statistically significant (table 3) .
Discussion
According to the literature, patients with ankylosing spondylitis might present with hearing loss secondary to their underlying disease. 5, 6 However, the characteristics of the audiologic profile of ankylosing spondylitis patients remain poorly understood.
In our study, the average of the mean air-conduction thresholds at 0.5, 1, 2, and 4 kHz was significantly higher in the case group than in the controls (p = 0.004). When thresholds were compared separately for each frequency, the case group had significantly higher thresholds than the control group at the higher frequencies: 3 kHz (p = 0.018), 4 kHz (p < 0.001), 6 kHz (p < 0.001), and 8 kHz (p = 0.001) (figure). These findings suggest that ankylosing spondylitis might lead to cochlear damage, especially in the basal and middle turns. Magarò et al described the case of an ankylosing spondylitis patient with conductive hearing loss secondary to arthritic involvement of the ossicular joints. 12 However, other studies have found an association between ankylosing spondylitis and SNHL, primarily in the higher frequencies, in the absence of middle ear pathology. 13, 14 We found no significant difference in BASDAI and BASFI scores between ankylosing spondylitis patients with and without hearing loss. This suggests that the level of disease activity and functional status did not correlate with the presence of hearing loss. In a similar vein, Kahveci et al found no correlation between speech recognition and BASDAI scores in their study. 15 It has been suggested that the SNHL in patients with ankylosing spondylitis is attributable not only to the disease itself, but also to drug-induced vasculitis of the labyrinthine artery or its cochlear branch. 16, 17 In a study conducted by Savastano et al, a subgroup of patients treated with anti-TNFα and methotrexate exhibited worse hearing thresholds than a subgroup who took only anti-TNFα. 16 Nevertheless, our study found no correlation between audiometric thresholds and the use of anti-TNFα, either alone or with methotrexate.
We did find a statistically significant difference between patients who took anti-TNFα and those who took other drugs (p = 0.001), suggesting that the use of anti-TNFα might be related to better hearing performance. However, our finding might have been skewed by differences in the duration of the disease among the subgroups, although differences in duration did not reach statistical significance.
Positive audiologic outcomes related to the use of anti-TNFα for the treatment of SNHL associated with spondyloarthropathies have been previously suggested by Jachiet et al. 17 They reported the case of a patient with severe SNHL, Crohn disease, and spondyloarthropathy who experienced a significant improvement in hearing thresholds after adalimumab was added to treatment with a corticosteroid.
The efficacy of TNFα blockade as a first-line therapy for autoimmune-mediated SNHL among patients with previous rheumatic disease is controversial because only a few studies on this topic have been conducted. However, studies already have documented that infliximab 18 and adalimumab 19 might have a beneficial effect. Future research is needed to better determine the underlying pathophysiology of SNHL among ankylosing spondylitis patients. With a better understanding of this, therapeutic options could be proposed and then validated in large, well-conducted clinical trials that would possibly transform this hearing impairment into a reversible condition. 
